Pile-on over PBMs con­tin­ues with FTC com­ments and a new bi­par­ti­san Sen­ate bill

More than 500 stake­hold­ers sent com­ments to the FTC on whether the com­mis­sion should look fur­ther in­to phar­ma mid­dle­men, known as PBMs, with many of the com­menters call­ing for more fed­er­al over­sight.

Sim­i­lar to the crit­i­cal open com­ment pe­ri­od in a dead­locked FTC ses­sion last Feb­ru­ary, phar­ma­cies and phar­ma­cy groups are con­tin­u­ing to call out the lack of trans­paren­cy among the top 3 PBMs, which con­trol about 80% of the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER